Interactions with Founders – Rahila Sardar and Sameer Malik, Vgenomics

Had a wonderful and thought-provoking meeting with the two passionate founders of Vgenomics, Dr. Rahila Sardar , Sameer Malik along with my investment partner Ishani Chanana Talwar at the Taj Palace, Delhi. The third founder Preeti Gupta Lal Ph.D is in US. We spent nearly three hours discussing their journey so far, their focused roadmap for the next 12 months, and laying the foundation for Horizon 2 and beyond.

I also had the privilege of signing and gifting them a copy of my book Dil Se Dost, a small token of shared values around purpose, resilience, and growth. We spent some time around purpose led , values driven , and focus on impact that Vgenomics plan to create

Here is a brief about Vgenomics:

Vgenomics is a biotechnology company specializing in early diagnosis and treatment solutions for rare genetic diseases. Leveraging genomics, bioinformatics and AI they offer comprehensive diagnostic solutions for multiple rare conditions, significantly reducing diagnostic timelines. Their AI platform enables clinicians and labs to make faster and more accurate decisions.

The Vgenomics team comprises experts from India and the USA, with a strong track record of multiple patents and research publications in leading journals. They have recently entered into a strategic partnership with Meril Genomics to advance genomics diagnostics. In collaboration with Dr. Shroff’s Charity Eye Hospital, they have also identified a novel biomarker for keratoconus progression, a condition considered a rare disease.

Vgenomics is paving the way for hospitals, diagnostic labs, and pharma companies to adopt innovative solutions for early detection and personalized treatment planning..

Key Takeaways from the Discussion:

 • Generate service revenues early to stay customer-centric and build long-term engagement.

 • Play a leadership role in spreading awareness about rare diseases and contribute to policy advocacy.

 • Collaborate aggressively with partners across both developed and emerging markets to expand reach and revenue streams.

 • Minimize upfront capital investment through creative pay-per-use and shared services models.

 • Deepen capabilities as both an R&D and a product-driven company to stay ahead of competition.

 • Align with like-minded investors who understand the domain and have a long-term commitment; explore non-dilutive funding like grants and concessional loans.

Wishing the Vgenomics team great success in their mission to transform the landscape of rare disease diagnostics and precision medicine.

April 2025